Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1280392rdf:typepubmed:Citationlld:pubmed
pubmed-article:1280392lifeskim:mentionsumls-concept:C0013336lld:lifeskim
pubmed-article:1280392lifeskim:mentionsumls-concept:C0013338lld:lifeskim
pubmed-article:1280392lifeskim:mentionsumls-concept:C0332307lld:lifeskim
pubmed-article:1280392lifeskim:mentionsumls-concept:C0037663lld:lifeskim
pubmed-article:1280392lifeskim:mentionsumls-concept:C0037657lld:lifeskim
pubmed-article:1280392lifeskim:mentionsumls-concept:C0018270lld:lifeskim
pubmed-article:1280392lifeskim:mentionsumls-concept:C0851285lld:lifeskim
pubmed-article:1280392pubmed:issue4lld:pubmed
pubmed-article:1280392pubmed:dateCreated1992-12-29lld:pubmed
pubmed-article:1280392pubmed:abstractTextInsulin-like growth factors (IGFs) mediate the effects of growth hormone (GH), and the insulin-like growth factor-binding proteins (IGFBPs) modulate the actions of IGFs in tissues. We studied the circulating levels of IGFBP-1 in 6 children and 9 adults with Laron type dwarfism (LTD), in 11 children and 21 adults with growth hormone deficiency (GHD), and in 8 children with constitutional short stature. Compared with the situation in healthy children, the basal serum IGFBP-1 concentration was 5.4-fold higher in LTD children, 4.1-fold higher in GHD children, and 3.8-fold higher in children with short stature (p < 0.02 vs controls in all groups). In adult patients with multiple pituitary hormone deficiency (MPHD), the IGFBP-1 concentration was 2-fold elevated, but it was normal in adult LTD patients. Intravenous (N = 10) or subcutaneous (N = 9) administration of IGF-I (75 micrograms.kg-1 and 150 micrograms.kg-1, respectively) in LTD children resulted in a rapid 50-60% fall in serum insulin (p < 0.02), a decline in blood glucose and a concomitant 40-60% rise of IGFBP-1 levels (p < 0.05). Treatment for seven days with IGF-I (150 micrograms.kg-1 x d-1) resulted in a decrease by 34% and 44% of serum IGFBP-1 level in two out of three children with LTD. After prolonged GH therapy, the IGFBP-1 level fell in GHD children by 29% (p < 0.05), in GHD adults by 52% (p < 0.02) and in children with constitutional short stature by 17% (p < 0.02).(ABSTRACT TRUNCATED AT 250 WORDS)lld:pubmed
pubmed-article:1280392pubmed:languageenglld:pubmed
pubmed-article:1280392pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1280392pubmed:citationSubsetIMlld:pubmed
pubmed-article:1280392pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1280392pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1280392pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1280392pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1280392pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1280392pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1280392pubmed:statusMEDLINElld:pubmed
pubmed-article:1280392pubmed:monthOctlld:pubmed
pubmed-article:1280392pubmed:issn0001-5598lld:pubmed
pubmed-article:1280392pubmed:authorpubmed-author:LaronZZlld:pubmed
pubmed-article:1280392pubmed:authorpubmed-author:SeppäläMMlld:pubmed
pubmed-article:1280392pubmed:authorpubmed-author:KoivistoV AVAlld:pubmed
pubmed-article:1280392pubmed:authorpubmed-author:PertzelanAAlld:pubmed
pubmed-article:1280392pubmed:authorpubmed-author:KlingerBBlld:pubmed
pubmed-article:1280392pubmed:authorpubmed-author:SilbergeldAAlld:pubmed
pubmed-article:1280392pubmed:authorpubmed-author:SuikkariA MAMlld:pubmed
pubmed-article:1280392pubmed:issnTypePrintlld:pubmed
pubmed-article:1280392pubmed:volume127lld:pubmed
pubmed-article:1280392pubmed:ownerNLMlld:pubmed
pubmed-article:1280392pubmed:authorsCompleteYlld:pubmed
pubmed-article:1280392pubmed:pagination351-8lld:pubmed
pubmed-article:1280392pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:1280392pubmed:meshHeadingpubmed-meshheading:1280392-...lld:pubmed
pubmed-article:1280392pubmed:meshHeadingpubmed-meshheading:1280392-...lld:pubmed
pubmed-article:1280392pubmed:meshHeadingpubmed-meshheading:1280392-...lld:pubmed
pubmed-article:1280392pubmed:meshHeadingpubmed-meshheading:1280392-...lld:pubmed
pubmed-article:1280392pubmed:meshHeadingpubmed-meshheading:1280392-...lld:pubmed
pubmed-article:1280392pubmed:meshHeadingpubmed-meshheading:1280392-...lld:pubmed
pubmed-article:1280392pubmed:meshHeadingpubmed-meshheading:1280392-...lld:pubmed
pubmed-article:1280392pubmed:meshHeadingpubmed-meshheading:1280392-...lld:pubmed
pubmed-article:1280392pubmed:meshHeadingpubmed-meshheading:1280392-...lld:pubmed
pubmed-article:1280392pubmed:meshHeadingpubmed-meshheading:1280392-...lld:pubmed
pubmed-article:1280392pubmed:meshHeadingpubmed-meshheading:1280392-...lld:pubmed
pubmed-article:1280392pubmed:meshHeadingpubmed-meshheading:1280392-...lld:pubmed
pubmed-article:1280392pubmed:meshHeadingpubmed-meshheading:1280392-...lld:pubmed
pubmed-article:1280392pubmed:meshHeadingpubmed-meshheading:1280392-...lld:pubmed
pubmed-article:1280392pubmed:year1992lld:pubmed
pubmed-article:1280392pubmed:articleTitleGrowth hormone and insulin-like growth factor regulate insulin-like growth factor-binding protein-1 in Laron type dwarfism, growth hormone deficiency and constitutional short stature.lld:pubmed
pubmed-article:1280392pubmed:affiliationInstitute of Pediatric and Adolescent Endocrinology, Beilinson Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Israel.lld:pubmed
pubmed-article:1280392pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1280392pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1280392lld:pubmed